Buscar
Vanda Pharmaceuticals Inc
VNDAAñadir a la lista de seguimiento
6.210USD
+0.160+2.64%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
373.44MCap. mercado
PérdidaP/E TTM
Más Datos de Vanda Pharmaceuticals Inc Compañía
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Información de Vanda Pharmaceuticals Inc
Símbolo de cotizaciónVNDA
Nombre de la empresaVanda Pharmaceuticals Inc
Fecha de salida a bolsaApr 12, 2006
Director ejecutivoPolymeropoulos (Mihael Hristos)
Número de empleados368
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 12
DirecciónSuite 300E
CiudadWASHINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20037
Teléfono12027343400
Sitio Webhttps://www.vandapharma.com/
Símbolo de cotizaciónVNDA
Fecha de salida a bolsaApr 12, 2006
Director ejecutivoPolymeropoulos (Mihael Hristos)
Ejecutivos de Vanda Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.59M
-70.28%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
219.05K
+18.99%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
204.77K
-141.34%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
160.67K
+25.89%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
128.47K
+32.38%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
122.59K
-236.09%
Dr. Stephen Ray Mitchell, M.D.
Dr. Stephen Ray Mitchell, M.D.
Independent Director
Independent Director
112.85K
+36.86%
Mr. Timothy I. Williams
Mr. Timothy I. Williams
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Ms. Phaedra S. Chrousos
Ms. Phaedra S. Chrousos
Independent Director
Independent Director
--
--
Mr. Joakim (Kim) Wijkstrom
Mr. Joakim (Kim) Wijkstrom
Senior Vice President, Chief Marketing Officer
Senior Vice President, Chief Marketing Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.59M
-70.28%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
219.05K
+18.99%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
204.77K
-141.34%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
160.67K
+25.89%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
128.47K
+32.38%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
122.59K
-236.09%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Vanda Pharmaceuticals Inc?
Los cinco principales accionistas de Vanda Pharmaceuticals Inc son: Dr. Mihael Hristos Polymeropoulos, M.D.
¿Cuántas instituciones poseen acciones de Vanda Pharmaceuticals Inc (VNDA)?
A fecha de 2026Q1, 353 instituciones poseen acciones de Vanda Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 47.15M, lo que representa el 78.40% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -5252737.00.
¿Cuál es la mayor fuente de ganancias de Vanda Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial Fanapt generó la ganancia más alta para Vanda Pharmaceuticals Inc, ascendiendo a 117.30M y representando el 54.28% de la ganancia total.